Dashboard
1
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate -291.70% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -2,163.53
2
Flat results in Dec 20
3
Risky -
4
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
HKD 19,301 Million ()
NA (Loss Making)
NA
0.00%
-0.92
-26.27%
3.11
Revenue and Profits:
Net Sales:
858 Million
(Quarterly Results - Jun 2025)
Net Profit:
-318 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-45.08%
0%
-45.08%
6 Months
-58.61%
0%
-58.61%
1 Year
-31.74%
0%
-31.74%
2 Years
-30.24%
0%
-30.24%
3 Years
-48.93%
0%
-48.93%
4 Years
-73.37%
0%
-73.37%
5 Years
-83.14%
0%
-83.14%
Zai Lab Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
50.36%
EBIT Growth (5y)
-291.70%
EBIT to Interest (avg)
-2,163.53
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.84
Sales to Capital Employed (avg)
0.14
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.52
EV to EBIT
-11.94
EV to EBITDA
-13.16
EV to Capital Employed
20.96
EV to Sales
6.89
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-175.59%
ROE (Latest)
-26.27%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Bearish
Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
858.40
828.50
3.61%
Operating Profit (PBDIT) excl Other Income
-376.10
-391.70
3.98%
Interest
9.80
9.20
6.52%
Exceptional Items
0.00
-14.90
100.00%
Consolidate Net Profit
-317.90
-376.90
15.65%
Operating Profit Margin (Excl OI)
-499.10%
-528.80%
2.97%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 3.61% vs -2.30% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 15.65% vs 40.66% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
3,113.30
2,088.10
49.10%
Operating Profit (PBDIT) excl Other Income
-2,043.10
-2,809.30
27.27%
Interest
17.60
0.00
Exceptional Items
-47.60
21.80
-318.35%
Consolidate Net Profit
-2,006.20
-2,619.70
23.42%
Operating Profit Margin (Excl OI)
-707.10%
-1,411.90%
70.48%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 49.10% vs 24.00% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 23.42% vs 24.53% in Dec 2023
About Zai Lab Ltd. 
Zai Lab Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






